Once-weekly GLP-1R agonists: Moving the goal posts

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

External organisations

  • Birmingham Health Partners
  • Department of Geriatric Medicine, Heart of England NHS Foundation Trust, Solihull Hospital, Birmingham, UK.
  • Aston University

Abstract

Glucagon like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes were first introduced to Europe and the USA in 2005.1 Since then, these compounds have become well-established treatment options in the management of type 2 diabetes.2 GLP-1 R agonists have several attractive features including potent and sustained glucose lowering, low risk of hypoglycaemia because of their glucose-dependent effects on insulin and glucagon secretion, sustained weight loss, and a favourable effect on cardiovascular risk factors together with reduction in cardiovascular event rates (liraglutide and semaglutide).

Details

Original languageEnglish
Pages (from-to)260-261
JournalThe Lancet Diabetes and Endocrinology
Volume6
Issue number4
Publication statusPublished - 31 Jan 2018